{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:48:35Z","timestamp":1793360915116,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Albireo Pharma, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s12325-022-02261-8","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T05:03:41Z","timestamp":1662440621000},"page":"5126-5143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Development of the Patient- and Observer-Reported PRUCISION Instruments to Assess Pruritus and Sleep Disturbance in Pediatric Patients with Cholestatic Liver Diseases"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8130-2024","authenticated-orcid":false,"given":"Chad","family":"Gwaltney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Bean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Venerus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Warholic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Kjems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"issue":"1","key":"2261_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4254\/wjh.v11.i1.19","volume":"11","author":"TJ Laborda","year":"2019","unstructured":"Laborda TJ, Jensen MK, Kavan M, Deneau M. Treatment of primary sclerosing cholangitis in children. World J Hepatol. 2019;11(1):19\u201336. https:\/\/doi.org\/10.4254\/wjh.v11.i1.19.","journal-title":"World J Hepatol"},{"issue":"28","key":"2261_CR2","doi-asserted-by":"publisher","first-page":"9418","DOI":"10.3748\/wjg.v20.i28.9418","volume":"20","author":"KD Nguyen","year":"2014","unstructured":"Nguyen KD, Sundaram V, Ayoub WS. Atypical causes of cholestasis. World J Gastroenterol. 2014;20(28):9418\u201326. https:\/\/doi.org\/10.3748\/wjg.v20.i28.9418.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"2261_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/mpg.0000000000001958","volume":"67","author":"BM Kamath","year":"2018","unstructured":"Kamath BM, Baker A, Houwen R, Todorova L, Kerkar N. Systematic review: the epidemiology, natural history, and burden of Alagille syndrome. J Pediatr Gastroenterol Nutr. 2018;67(2):148\u201356. https:\/\/doi.org\/10.1097\/mpg.0000000000001958.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"2261_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","volume":"51","author":"European Association for the Study of the Liver","year":"2009","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237\u201367. https:\/\/doi.org\/10.1016\/j.jhep.2009.04.009.","journal-title":"J Hepatol"},{"key":"2261_CR5","doi-asserted-by":"publisher","unstructured":"Wehrman A, Waisbourd-Zinman O, Wells RG. Recent advances in understanding biliary atresia. F1000Res. 2019;8:F1000. https:\/\/doi.org\/10.12688\/f1000research.16732.1.","DOI":"10.12688\/f1000research.16732.1"},{"key":"2261_CR6","unstructured":"Bylvay [package insert]. Boston: Albireo Pharma, Inc.; 2021."},{"key":"2261_CR7","unstructured":"Bylvay [summary of product characteristics]. G\u00f6teborg: Albireo AB; 2021."},{"key":"2261_CR8","unstructured":"Livmarli (maralixibat) [prescribing information]. Foster City: Mirum Pharmaceuticals, Inc.; 2021."},{"issue":"1","key":"2261_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/lt.24640","volume":"23","author":"SS Sundaram","year":"2017","unstructured":"Sundaram SS, Mack CL, Feldman AG, Sokol RJ. Biliary atresia: indications and timing of liver transplantation and optimization of pretransplant care. Liver Transpl. 2017;23(1):96\u2013109. https:\/\/doi.org\/10.1002\/lt.24640.","journal-title":"Liver Transpl"},{"issue":"3","key":"2261_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/ejhg.2011.181","volume":"20","author":"PD Turnpenny","year":"2012","unstructured":"Turnpenny PD, Ellard S. Alagille syndrome: pathogenesis, diagnosis and management. Eur J Hum Genet. 2012;20(3):251\u20137. https:\/\/doi.org\/10.1038\/ejhg.2011.181.","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"2261_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clinre.2017.08.007","volume":"42","author":"A Th\u00e9baut","year":"2018","unstructured":"Th\u00e9baut A, Debray D, Gonzales E. An update on the physiopathology and therapeutic management of cholestatic pruritus in children. Clin Res Hepatol Gastroenterol. 2018;42(2):103\u20139. https:\/\/doi.org\/10.1016\/j.clinre.2017.08.007.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"1","key":"2261_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.clinre.2018.07.010","volume":"43","author":"A Baker","year":"2019","unstructured":"Baker A, Kerkar N, Todorova L, Kamath BM, Houwen RHJ. Systematic review of progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol. 2019;43(1):20\u201336. https:\/\/doi.org\/10.1016\/j.clinre.2018.07.010.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"8","key":"2261_CR13","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s00431-018-3181-3","volume":"177","author":"BL Meena","year":"2018","unstructured":"Meena BL, Khanna R, Bihari C, Rastogi A, Rawat D, Alam S. Bile duct paucity in childhood-spectrum, profile, and outcome. Eur J Pediatr. 2018;177(8):1261\u20139. https:\/\/doi.org\/10.1007\/s00431-018-3181-3.","journal-title":"Eur J Pediatr"},{"issue":"2","key":"2261_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.clinre.2010.10.007","volume":"35","author":"AE Kremer","year":"2011","unstructured":"Kremer AE, Oude Elferink RP, Beuers U. Pathophysiology and current management of pruritus in liver disease. Clin Res Hepatol Gastroenterol. 2011;35(2):89\u201397. https:\/\/doi.org\/10.1016\/j.clinre.2010.10.007.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"2","key":"2261_CR15","doi-asserted-by":"publisher","first-page":"278","DOI":"10.5500\/wjt.v6.i2.278","volume":"6","author":"A Mehl","year":"2016","unstructured":"Mehl A, Bohorquez H, Serrano MS, Galliano G, Reichman TW. Liver transplantation and the management of progressive familial intrahepatic cholestasis in children. World J Transplant. 2016;6(2):278\u201390. https:\/\/doi.org\/10.5500\/wjt.v6.i2.278.","journal-title":"World J Transplant"},{"issue":"7","key":"2261_CR16","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jval.2017.05.015","volume":"20","author":"K Benjamin","year":"2017","unstructured":"Benjamin K, Vernon MK, Patrick DL, Perfetto E, Nestler-Parr S, Burke L. Patient-reported outcome and observer-reported outcome assessment in rare disease clinical trials: an ISPOR COA Emerging Good Practices Task Force report. Value Health. 2017;20(7):838\u201355. https:\/\/doi.org\/10.1016\/j.jval.2017.05.015.","journal-title":"Value Health"},{"issue":"6","key":"2261_CR17","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jval.2015.08.006","volume":"18","author":"MK Walton","year":"2015","unstructured":"Walton MK, Powers JH 3rd, Hobart J, Patrick D, Marquis P, Vamvakas S, et al. Clinical outcome assessments: conceptual foundation-report of the ISPOR Clinical Outcomes Assessment\u2014Emerging Good Practices for Outcomes Research Task Force. Value Health. 2015;18(6):741\u201352. https:\/\/doi.org\/10.1016\/j.jval.2015.08.006.","journal-title":"Value Health"},{"key":"2261_CR18","unstructured":"U.S. Department of Health and Human Services. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009. http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM193282.pdf. Accessed June 13, 2022."},{"key":"2261_CR19","unstructured":"Committee for Medicinal Products for Human Use. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. 2005. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-regulatory-guidance-use-healthrelated-quality-life-hrql-measures-evaluation_en.pdf. Accessed June 13, 2022."},{"issue":"8","key":"2261_CR20","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity\u2013establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 1\u2013eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967\u201377. https:\/\/doi.org\/10.1016\/j.jval.2011.06.014.","journal-title":"Value Health"},{"issue":"8","key":"2261_CR21","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity\u2013establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2\u2013assessing respondent understanding. Value Health. 2011;14(8):978\u201388. https:\/\/doi.org\/10.1016\/j.jval.2011.06.013.","journal-title":"Value Health"},{"issue":"3","key":"2261_CR22","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/hep.29905","volume":"68","author":"JA Bezerra","year":"2018","unstructured":"Bezerra JA, Wells RG, Mack CL, Karpen SJ, Hoofnagle JH, Doo E, et al. Biliary atresia: clinical and research challenges for the twenty-first century. Hepatology. 2018;68(3):1163\u201373. https:\/\/doi.org\/10.1002\/hep.29905.","journal-title":"Hepatology"},{"issue":"1","key":"2261_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1609406917702983","volume":"16","author":"KKF Cheng","year":"2017","unstructured":"Cheng KKF, Clark AM. Qualitative methods and patient-reported outcomes: measures development and adaptation. Int J Qual Methods. 2017;16(1):1\u20133. https:\/\/doi.org\/10.1177\/1609406917702983.","journal-title":"Int J Qual Methods"},{"issue":"1","key":"2261_CR24","first-page":"39","volume":"46","author":"FA Al-Qarqaz","year":"2012","unstructured":"Al-Qarqaz FA, Al Aboosi M, Al-Shiyab D, Bataineh A. Using pruritus grading system for measurement of pruritus in patients with diseases associated with itch. J Med J. 2012;46(1):39\u201344.","journal-title":"J Med J"},{"issue":"5","key":"2261_CR25","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/j.1365-2133.2009.09328.x","volume":"161","author":"C Blome","year":"2009","unstructured":"Blome C, Augustin M, Siepmann D, Phan NQ, Rustenbach SJ, St\u00e4nder S. Measuring patient-relevant benefits in pruritus treatment: development and validation of a specific outcomes tool. Br J Dermatol. 2009;161(5):1143\u20138. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09328.x.","journal-title":"Br J Dermatol"},{"issue":"1\u20133","key":"2261_CR26","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1159\/000053748","volume":"124","author":"U Darsow","year":"2001","unstructured":"Darsow U, Scharein E, Simon D, Walter G, Bromm B, Ring J. New aspects of itch pathophysiology: component analysis of atopic itch using the \u201cEppendorf Itch Questionnaire.\u201d Int Arch Allergy Immunol. 2001;124(1\u20133):326\u201331. https:\/\/doi.org\/10.1159\/000053748.","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"2261_CR27","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jaad.2008.04.006","volume":"59","author":"NS Desai","year":"2008","unstructured":"Desai NS, Poindexter GB, Monthrope YM, Bendeck SE, Swerlick RA, Chen SC. A pilot quality-of-life instrument for pruritus. J Am Acad Dermatol. 2008;59(2):234\u201344. https:\/\/doi.org\/10.1016\/j.jaad.2008.04.006.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2261_CR28","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1365-2133.2009.09586.x","volume":"162","author":"S Elman","year":"2010","unstructured":"Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. Br J Dermatol. 2010;162(3):587\u201393. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09586.x.","journal-title":"Br J Dermatol"},{"issue":"6","key":"2261_CR29","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/j.1365-2133.1995.tb16953.x","volume":"132","author":"MS Lewis-Jones","year":"1995","unstructured":"Lewis-Jones MS, Finlay AY. The Children\u2019s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942\u20139. https:\/\/doi.org\/10.1111\/j.1365-2133.1995.tb16953.x.","journal-title":"Br J Dermatol"},{"issue":"4","key":"2261_CR30","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/j.1365-2133.2006.07736.x","volume":"156","author":"CJ Majeski","year":"2007","unstructured":"Majeski CJ, Johnson JA, Davison SN, Lauzon CJ. Itch Severity Scale: a self-report instrument for the measurement of pruritus severity. Br J Dermatol. 2007;156(4):667\u201373. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07736.x.","journal-title":"Br J Dermatol"},{"issue":"5","key":"2261_CR31","doi-asserted-by":"publisher","first-page":"502","DOI":"10.2340\/00015555-1246","volume":"92","author":"NQ Phan","year":"2012","unstructured":"Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92(5):502\u20137. https:\/\/doi.org\/10.2340\/00015555-1246.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"2261_CR32","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1080\/00015550152384236","volume":"81","author":"G Yosipovitch","year":"2001","unstructured":"Yosipovitch G, Zucker I, Boner G, Gafter U, Shapira Y, David M. A questionnaire for the assessment of pruritus: validation in uremic patients. Acta Derm Venereol. 2001;81(2):108\u201311. https:\/\/doi.org\/10.1080\/00015550152384236.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"2261_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/MPG.0b013e318297e384","volume":"57","author":"V Kronsten","year":"2013","unstructured":"Kronsten V, Fitzpatrick E, Baker A. Management of cholestatic pruritus in paediatric patients with Alagille syndrome: the King\u2019s College Hospital experience. J Pediatr Gastroenterol Nutr. 2013;57(2):149\u201354. https:\/\/doi.org\/10.1097\/MPG.0b013e318297e384.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2261_CR34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1750-1172-9-89","volume":"9","author":"Y Hasegawa","year":"2014","unstructured":"Hasegawa Y, Hayashi H, Naoi S, Kondou H, Bessho K, Igarashi K, et al. Intractable itch relieved by 4-phenylbutyrate therapy in patients with progressive familial intrahepatic cholestasis type 1. Orphanet J Rare Dis. 2014;9:89. https:\/\/doi.org\/10.1186\/1750-1172-9-89.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2261_CR35","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/0016-5085(88)90301-0","volume":"95","author":"PF Whitington","year":"1988","unstructured":"Whitington PF, Whitington GL. Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. Gastroenterology. 1988;95(1):130\u20136. https:\/\/doi.org\/10.1016\/0016-5085(88)90301-0.","journal-title":"Gastroenterology"},{"issue":"8","key":"2261_CR36","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1002\/hep4.1970","volume":"6","author":"BL Shneider","year":"2022","unstructured":"Shneider BL, Kamath BM, Magee JC, Goodrich NP, Loomes KM, Ye W, et al. Use of funded multicenter prospective longitudinal databases to inform clinical trials in rare diseases\u2014examination of cholestatic liver disease in Alagille syndrome. Hepatol Commun. 2022;6(8):1910\u201321. https:\/\/doi.org\/10.1002\/hep4.1970.","journal-title":"Hepatol Commun."},{"issue":"9","key":"2261_CR37","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S2468-1253(22)00093-0","volume":"7","author":"RJ Thompson","year":"2022","unstructured":"Thompson RJ, Arnell H, Artan R, Baumann U, Calvo PL, Czubkowski P, et al. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2022;7(9):830-842. https:\/\/doi.org\/10.1016\/S2468-1253(22)00093-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"2261_CR38","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/hep4.1567","volume":"4","author":"HP Kim","year":"2020","unstructured":"Kim HP, Lieber SR, Rogers ME, Moon AM, Loiselle M, Walker J, et al. A systematic review of patient-reported outcomes in primary biliary cholangitis and primary sclerosing cholangitis. Hepatol Commun. 2020;4(10):1502\u201315. https:\/\/doi.org\/10.1002\/hep4.1567.","journal-title":"Hepatol Commun"},{"issue":"2","key":"2261_CR39","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11901-020-00517-x","volume":"19","author":"MM D\u00fcll","year":"2020","unstructured":"D\u00fcll MM, Kremer AE. Newer approaches to the management of pruritus in cholestatic liver disease. Curr Hepatol Rep. 2020;19(2):86\u201395. https:\/\/doi.org\/10.1007\/s11901-020-00517-x.","journal-title":"Curr Hepatol Rep"},{"issue":"5","key":"2261_CR40","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2340\/00015555-1620","volume":"93","author":"S Stander","year":"2013","unstructured":"Stander S, Augustin M, Reich A, Blome C, Ebata T, Phan NQ, et al. Pruritus assessment in clinical trials: consensus recommendations from the International Forum for the Study of Itch (IFSI) Special Interest Group Scoring Itch in Clinical Trials. Acta Derm Venereol. 2013;93(5):509\u201314. https:\/\/doi.org\/10.2340\/00015555-1620.","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"2261_CR41","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/j.1398-9995.2011.02577.x","volume":"66","author":"JF Stalder","year":"2011","unstructured":"Stalder JF, Barbarot S, Wollenberg A, Holm EA, De Raeve L, Seidenari S, et al. Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy. 2011;66(8):1114\u201321. https:\/\/doi.org\/10.1111\/j.1398-9995.2011.02577.x.","journal-title":"Allergy"},{"issue":"5","key":"2261_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101751","volume":"45","author":"U Baumann","year":"2021","unstructured":"Baumann U, Sturm E, Lacaille F, Gonzales E, Arnell H, Fischler B, et al. Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: phase 2 study. Clin Res Hepatol Gastroenterol. 2021;45(5):101751.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"3","key":"2261_CR43","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ajg.2021.04.001","volume":"22","author":"N El Koofy","year":"2021","unstructured":"El Koofy N, Yassin N, Okasha S, William H, Elakel W, Elshiwy Y. Evaluation of the role of bile acids and serotonin as markers of pruritus in children with chronic cholestatic liver disease. Arab J Gastroenterol. 2021;22(3):199\u2013202. https:\/\/doi.org\/10.1016\/j.ajg.2021.04.001.","journal-title":"Arab J Gastroenterol"},{"issue":"4","key":"2261_CR44","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/00005176-199910000-00013","volume":"29","author":"B Yerushalmi","year":"1999","unstructured":"Yerushalmi B, Sokol RJ, Narkewicz MR, Smith D, Karrer FM. Use of rifampin for severe pruritus in children with chronic cholestasis. J Pediatr Gastroenterol Nutr. 1999;29(4):442\u20137.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"10","key":"2261_CR45","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/hep4.1244","volume":"2","author":"BL Shneider","year":"2018","unstructured":"Shneider BL, Spino C, Kamath BM, Magee JC, Bass LM, Setchell KD, et al. Placebo-controlled randomized trial of an intestinal bile salt transport inhibitor for pruritus in Alagille syndrome. Hepatol Commun. 2018;2(10):1184\u201398. https:\/\/doi.org\/10.1002\/hep4.1244.","journal-title":"Hepatol Commun"},{"issue":"1","key":"2261_CR46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40271-017-0266-4","volume":"11","author":"BM Kamath","year":"2018","unstructured":"Kamath BM, Abetz-Webb L, Kennedy C, Hepburn B, Gauthier M, Johnson N, et al. Development of a novel tool to assess the impact of itching in pediatric cholestasis. Patient. 2018;11(1):69\u201382. https:\/\/doi.org\/10.1007\/s40271-017-0266-4.","journal-title":"Patient"},{"key":"2261_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1980","author":"KM Loomes","year":"2022","unstructured":"Loomes KM, Squires RH, Kelly D, Rajwal S, Soufi N, Lachaux A, et al. Maralixibat for the treatment of PFIC: long-term, IBAT inhibition in an open-label, phase 2 study. Hepatol Commun. 2022. https:\/\/doi.org\/10.1002\/hep4.1980.","journal-title":"Hepatol Commun."},{"issue":"4","key":"2261_CR48","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jval.2013.04.004","volume":"16","author":"LS Matza","year":"2013","unstructured":"Matza LS, Patrick DL, Riley AW, Alexander JJ, Rajmil L, Pleil AM, et al. Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force. Value Health. 2013;16(4):461\u201379. https:\/\/doi.org\/10.1016\/j.jval.2013.04.004.","journal-title":"Value Health"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02261-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02261-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02261-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T15:49:35Z","timestamp":1664552975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02261-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["2261"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02261-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"assertion":[{"value":"26 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}